Pair your accounts.

Export articles to Mendeley

Get article recommendations from ACS based on references in your Mendeley library.

Pair your accounts.

Export articles to Mendeley

Get article recommendations from ACS based on references in your Mendeley library.

You’ve supercharged your research process with ACS and Mendeley!

Click to create an ACS ID

Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

Your Mendeley pairing has expired. Please reconnect
ACS Publications. Most Trusted. Most Cited. Most Read
My Activity

Figure 1Loading Img

Mapping the Ligand-Binding Site on the C5a Receptor:  Arginine74 of C5a Contacts Aspartate282 of the C5a Receptor

View Author Information
Department of Neurology, University of Sheffield Medical School, Sheffield S10 2RX, U.K.
Cite this: Biochemistry 2001, 40, 46, 14047–14052
Publication Date (Web):October 25, 2001
Copyright © 2001 American Chemical Society

    Article Views





    Other access options


    The interaction between the anaphylatoxin C5a and its receptor involves two distinct sites. One site is formed by acidic residues at the receptor N-terminus and contributes to only ligand binding. The second site, responsible for activation, is less well defined. In this study, we demonstrate that the receptor residue D282, near the extracellular face of transmembrane domain VII, is a component of the second ligand-binding site. Mutation of D282 to A decreases the sensitivity of the receptor to activation by intact C5a but not by its less potent metabolite, C5adR74, which lacks the C-terminal arginine74. The mutation of the R74 residue of C5a to A causes a 60-fold decrease in wild-type receptor sensitivity, but only a 2-fold decrease for the receptor mutated at D282. In contrast, the mutation of R74 to D makes C5a completely inactive on both wild-type and A282 C5a receptors. The mutation of D282 to R partly restores the response to C5a[D74], which is a more effective ligand than C5a at the mutant receptor. A peptide mimic of the C5a activation domain with a C-terminal R potently activates the wild type but is only a weak agonist at the mutant D282R-C5a receptor. Conversely, a peptide with D at the C-terminus is a more effective activator of D282R than wild-type C5a receptors. These data indicate that the R74 side chain of C5a makes an interaction with receptor D282 that is responsible for the higher potency of intact C5a versus that of C5adR74.

    Read this article

    To access this article, please review the available access options below.

    Get instant access

    Purchase Access

    Read this article for 48 hours. Check out below using your ACS ID or as a guest.


    Access through Your Institution

    You may have access to this article through your institution.

    Your institution does not have access to this content. You can change your affiliated institution below.

     This work was supported by grants from the Arthritis Research Campaign (M0543) and the Wellcome Trust (007521).

     Present address:  Department of Human Morphology, University of Nottingham, Nottingham NG7 2RD, U.K.


     To whom correspondence should be addressed. Telephone:  +44 114 2261312. Fax:  +44 114 2760095. E-mail:  [email protected].

    Cited By

    This article is cited by 27 publications.

    1. An Xiaoli, Niu Yuzhen, Yang Qiong, Lei Yang, Xiaojun Yao, Zhitong Bing. Investigating the Dynamic Binding Behavior of PMX53 Cooperating with Allosteric Antagonist NDT9513727 to C5a Anaphylatoxin Chemotactic Receptor 1 through Gaussian Accelerated Molecular Dynamics and Free-Energy Perturbation Simulations. ACS Chemical Neuroscience 2022, 13 (23) , 3502-3511.
    2. Gregory V. Nikiforovich, Garland R. Marshall and Thomas J. Baranski . Modeling Molecular Mechanisms of Binding of the Anaphylatoxin C5a to the C5a Receptor. Biochemistry 2008, 47 (10) , 3117-3130.
    3. Yue Wang, Weiyi Liu, Youwei Xu, Xinheng He, Qingning Yuan, Ping Luo, Wenjia Fan, Jingpeng Zhu, Xinyue Zhang, Xi Cheng, Yi Jiang, H. Eric Xu, Youwen Zhuang. Revealing the signaling of complement receptors C3aR and C5aR1 by anaphylatoxins. Nature Chemical Biology 2023, 19 (11) , 1351-1360.
    4. Lisen Li, Weining Yang, Yubang Shen, Xiaoyan Xu, Jiale Li. The evolutionary analysis of complement component C5 and the gene co–expression network and putative interaction between C5a and C5a anaphylatoxin receptor (C5AR/CD88) in human and two Cyprinid fish. Developmental & Comparative Immunology 2021, 116 , 103958.
    5. Heng Liu, Hee Ryung Kim, R. N. V. Krishna Deepak, Lei Wang, Ka Young Chung, Hao Fan, Zhiyi Wei, Cheng Zhang. Orthosteric and allosteric action of the C5a receptor antagonists. Nature Structural & Molecular Biology 2018, 25 (6) , 472-481.
    6. Soumendra Rana, Amita Rani Sahoo, Bharat Kumar Majhi. Allosterism in human complement component 5a ( h C5a): a damper of C5a receptor (C5aR) signaling. Journal of Biomolecular Structure and Dynamics 2016, 34 (6) , 1201-1213.
    7. Lisa Joedicke, Raphael Trenker, Julian D. Langer, Hartmut Michel, Julia Preu. Cell‐free synthesis of isotopically labelled peptide ligands for the functional characterization of G protein‐coupled receptors. FEBS Open Bio 2016, 6 (1) , 90-102.
    8. Soumendra Rana, Amita Rani Sahoo. Model structures of inactive and peptide agonist bound C5aR: Insights into agonist binding, selectivity and activation. Biochemistry and Biophysics Reports 2015, 1 , 85-96.
    9. Phanourios Tamamis, Chris A Kieslich, Gregory V Nikiforovich, Trent M Woodruff, Dimitrios Morikis, Georgios Archontis. Insights into the mechanism of C5aR inhibition by PMX53 via implicit solvent molecular dynamics simulations and docking. BMC Biophysics 2014, 7 (1)
    10. Andreas Klos, Elisabeth Wende, Kathryn J. Wareham, Peter N. Monk. International Union of Basic and Clinical Pharmacology. LXXXVII. Complement Peptide C5a, C4a, and C3a Receptors. Pharmacological Reviews 2013, 65 (1) , 500-543.
    11. Soumendra Rana, Thomas J. Baranski. Third Extracellular Loop (EC3)-N Terminus Interaction Is Important for Seven-transmembrane Domain Receptor Function. Journal of Biological Chemistry 2010, 285 (41) , 31472-31483.
    12. Ian S. Hagemann, Daniel L. Miller, Jeffery M. Klco, Gregory V. Nikiforovich, Thomas J. Baranski. Structure of the Complement Factor 5a Receptor-Ligand Complex Studied by Disulfide Trapping and Molecular Modeling. Journal of Biological Chemistry 2008, 283 (12) , 7763-7775.
    13. P N Monk, A‐M Scola, P Madala, D P Fairlie. Function, structure and therapeutic potential of complement C5a receptors. British Journal of Pharmacology 2007, 152 (4) , 429-448.
    14. Anne-Marie Scola, Adrian Higginbottom, Lynda J. Partridge, Robert C. Reid, Trent Woodruff, Stephen M. Taylor, David P. Fairlie, Peter N. Monk. The Role of the N-terminal Domain of the Complement Fragment Receptor C5L2 in Ligand Binding. Journal of Biological Chemistry 2007, 282 (6) , 3664-3671.
    15. Tetsuro Yamamoto. Roles of the ribosomal protein S19 dimer and the C5a receptor in pathophysiological functions of phagocytic leukocytes. Pathology International 2007, 57 (1) , 1-11.
    16. Lavinia M Proctor, Trent M Woodruff, Stephen M Taylor. Recent developments in C5/C5a inhibitors. Expert Opinion on Therapeutic Patents 2006, 16 (4) , 445-458.
    17. Jean‐Sebastien Surgand, Jordi Rodrigo, Esther Kellenberger, Didier Rognan. A chemogenomic analysis of the transmembrane binding cavity of human G‐protein‐coupled receptors. Proteins: Structure, Function, and Bioinformatics 2006, 62 (2) , 509-538.
    18. Reto Bader, Oliver Zerbe. Are Hormones from the Neuropeptide Y Family Recognized by Their Receptors from the Membrane‐Bound State?. ChemBioChem 2005, 6 (9) , 1520-1534.
    19. Adrian Higginbottom, Stuart A. Cain, Trent M. Woodruff, Lavinia M. Proctor, Praveen K. Madala, Joel D.A. Tyndall, Stephen M. Taylor, David P. Fairlie, Peter N. Monk. Comparative Agonist/Antagonist Responses in Mutant Human C5a Receptors Define the Ligand Binding Site. Journal of Biological Chemistry 2005, 280 (18) , 17831-17840.
    20. Elizabeth Buck, Henry Bourne, James A. Wells. Site-specific Disulfide Capture of Agonist and Antagonist Peptides on the C5a Receptor. Journal of Biological Chemistry 2005, 280 (6) , 4009-4012.
    21. Hani Boshra, Jun Li, Rodney Peters, John Hansen, Anjan Matlapudi, J. Oriol Sunyer. Cloning, Expression, Cellular Distribution, and Role in Chemotaxis of a C5a Receptor in Rainbow Trout: The First Identification of a C5a Receptor in a Nonmammalian Species. The Journal of Immunology 2004, 172 (7) , 4381-4390.
    22. Magnus Otto, Heiko Hawlisch, Peter N. Monk, Melanie Müller, Andreas Klos, Christopher L. Karp, Jörg Köhl. C5a Mutants Are Potent Antagonists of the C5a Receptor (CD88) and of C5L2. Journal of Biological Chemistry 2004, 279 (1) , 142-151.
    23. Stuart A. Cain, Adrian Higginbottom, Peter N. Monk. Characterisation of C5a receptor agonists from phage display libraries. Biochemical Pharmacology 2003, 66 (9) , 1833-1840.
    24. Markus S. Huber-Lang, J. Vidya Sarma, Stephanie R. McGuire, Kristina T. Lu, Vaishalee A. Padgaonkar, Ellen M. Younkin, Ren Feng Guo, Christian H. Weber, Erik R. Zuiderweg, Firas S. Zetoune, Peter A. Ward. Structure-Function Relationships of Human C5a and C5aR. The Journal of Immunology 2003, 170 (12) , 6115-6124.
    25. David Kalant, Stuart A. Cain, Magdalena Maslowska, Allan D Sniderman, Katherine Cianflone, Peter N. Monk. The Chemoattractant Receptor-like Protein C5L2 Binds the C3a des-Arg77/Acylation-stimulating Protein. Journal of Biological Chemistry 2003, 278 (13) , 11123-11129.
    26. Stuart A. Cain, Peter N. Monk. The Orphan Receptor C5L2 Has High Affinity Binding Sites for Complement Fragments C5a and C5a des-Arg74. Journal of Biological Chemistry 2002, 277 (9) , 7165-7169.
    27. David E. Metzler, Carol M. Metzler, David J. Sauke. Biochemical Defense Mechanisms. 2001, 1831-1877.